Findings suggest GD2-specific CAR T-cell therapy is a viable option for H3K27M-mutant gliomas, with significant tumor ...

Immune-cell therapy shrank children's brain tumors, restored neurologic function and—for one participant—erased all ...

In a trial with 11 patients with midline diffuse glioma, 9 showed benefits from the cellular therapy. In one case, the tumor ...

Our current research focus is on pediatric high grade glioma (pHGG) driven by histone mutations including H3G34R mutations observed hemispheric tumors and H3K27M mutations seen in diffuse intrinsic ...

“RANO 2.0 is a recently established response assessment criteria for gliomas that supersedes prior versions such as RANO-HGG and RANO-LGG. RANO 2.0 incorporates an integrated quantitative ...

Title: Response by RANO 2.0 criteria in ONC201 (dordaviprone)-treated patients with recurrent H3 K27M-mutant diffuse midline glioma Abstract Code: CTNI-54 Session Date and Time: Friday, November 22, ...

"We are excited to provide an updated assessment of objective response to dordaviprone previously reported in the blinded independent central review (BICR) cohort 1 in recurrent H3 K27M-mutant diffuse ...